Business Context and Reporting Period
This Form 8-K is a current report filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on February 13, 2018. The registrant is an emerging growth company incorporated in Nevada. The filing serves to disclose a presentation utilized by the Company at the BIO CEO & Investor Conference held in New York on February 12–13, 2018.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a presentation (Exhibit 99.1) and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this specific filing. The document solely references the dissemination of a presentation to investors.
Guidance, Outlook, and Risks
- Management Commentary: The Company furnished a presentation to the market, which is attached as Exhibit 99.1. The content of this presentation is not incorporated by reference into this filing.
- Forward-Looking Statements: The filing includes a standard disclaimer that statements regarding future matters are subject to risks and uncertainties. Actual results may differ materially from those expressed.
- Risks: Specific risks are described in the Company's most recent Form 10-Q and other SEC filings, rather than in this 8-K.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (the presentation) separately, as it is not incorporated by reference into this filing.
- Confirm the Company's current name and status, noting the registrant is Nemus Bioscience, Inc., not Skye Bioscience, Inc.
- Review the most recent Form 10-Q for detailed financial metrics and risk factors, as this 8-K contains no financial data.
- Note that the Company has elected to use the extended transition period for complying with new accounting standards as an emerging growth company.